Neoadjuvant Chemotherapy in Combination with Toripalimab

DRUG3 trials

Sponsors

First Affiliated Hospital of Zhejiang University

Conditions

HR Positive/HER2 Low Breast CancerHR+/HER2- Breast Cancer

Phase 2

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

RecruitingNCT06611813

First Affiliated Hospital of Zhejiang UniversityHR+/HER2- Breast Cancer

Start: 2024-06-11End: 2029-06-30Target: 30Updated: 2025-08-12

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

RecruitingNCT07383818

First Affiliated Hospital of Zhejiang UniversityHR Positive/HER2 Low Breast Cancer

Start: 2026-02-01End: 2031-02-01Target: 111Updated: 2026-02-03

Phase 3

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

RecruitingNCT06977893

First Affiliated Hospital of Zhejiang UniversityHR+/HER2- Breast Cancer

Start: 2025-03-24End: 2030-03-23Target: 194Updated: 2025-05-18